Tufts study suggests carvedilol won’t blunt doxorubicin in HSA

A Tufts-led research team is reporting early evidence that carvedilol may be compatible with doxorubicin in canine hemangiosarcoma treatment, a useful signal for veterinarians balancing cancer control against cardiac risk. In laboratory assays, carvedilol had a small independent effect on reducing hemangiosarcoma cell viability at higher concentrations, and it did not appear to reduce doxorubicin’s effectiveness when the two drugs were used together. The project was led in the Yang Laboratory at Cummings School of Veterinary Medicine and featured work by cardiology research intern Dr. Kate Murphy and veterinary student Jessie King. (vet.tufts.edu)

The question is clinically relevant because doxorubicin remains one of the most commonly used chemotherapy agents for canine hemangiosarcoma, including splenic and cardiac forms, despite its known cardiotoxic potential. Cornell notes that hemangiosarcoma is a highly malignant vascular cancer seen most often in older, large-breed dogs, and doxorubicin is commonly given every three weeks for five treatments. Retrospective data published in JVIM found clinical cardiotoxicity in 4.0% of dogs overall, but the rate was higher, 15.4%, in breeds at elevated risk for dilated cardiomyopathy. (vet.cornell.edu)

That tension has helped drive interest in veterinary cardio-oncology. Tufts’ September 16, 2026, report says the team set out to determine whether carvedilol, a beta-blocker sometimes prescribed to mitigate doxorubicin-related cardiac effects, could be given without compromising antitumor efficacy. According to Murphy’s assay work, higher carvedilol doses modestly reduced hemangiosarcoma cell viability, and combined carvedilol-doxorubicin treatment still produced substantial, statistically significant cell death. King’s portion of the project then examined beta-adrenergic pathways to better understand why carvedilol affected some patient-derived cancer cells more than others. (vet.tufts.edu)

The broader science gives that result some context. Beta-adrenergic signaling has been described as a targetable regulator in angiosarcoma and hemangiosarcoma biology, and other beta-blocker work, especially with propranolol, has suggested that adrenergic blockade can have direct or adjunctive antitumor effects in vascular sarcomas. A 2021 mechanistic study found propranolol sensitized canine hemangiosarcoma and human angiosarcoma cells to doxorubicin, while a more recent phase I canine study evaluated propranolol plus doxorubicin in dogs with splenic hemangiosarcoma. That doesn’t make carvedilol interchangeable with propranolol, but it does suggest this drug class is already under active comparative-oncology scrutiny. (pubmed.ncbi.nlm.nih.gov)

On the cardioprotection side, the evidence base is still developing. A 2021 prospective, randomized, double-blind, placebo-controlled pilot study in dogs receiving doxorubicin found some echocardiographic and electrocardiographic indices were less affected in the carvedilol group, suggesting possible benefit. More recently, a 2025 translational study reported that in 18 dogs with spontaneous hemangiosarcoma randomized during doxorubicin treatment, declines in fractional shortening and some myocardial structural changes were not statistically significant in the cardioprotective arm receiving carvedilol plus lisinopril, whereas those changes were observed after doxorubicin overall. An ACVIM Forum session in 2025 also underscored that anthracycline cardiotoxicity remains a live debate between cardiologists and oncologists, particularly in cancers such as lymphoma and hemangiosarcoma. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For practicing veterinarians, especially oncologists, cardiologists, and referral teams, the Tufts findings help narrow one uncertainty: whether adding carvedilol is likely to interfere with doxorubicin at the tumor-cell level. The answer from this early work appears reassuring, but only within the limits of an in vitro study. It doesn’t yet establish the right dose, timing, patient selection, or monitoring strategy in clinic, and it doesn’t answer whether carvedilol improves survival, reduces symptomatic heart disease, or changes chemotherapy completion rates. For high-risk breeds or dogs with longer expected survival, those clinical endpoints will matter more than cell viability data alone. (vet.tufts.edu)

What to watch: The next milestones are a formal peer-reviewed publication of the Tufts cell-line work, clearer reporting from the Tufts canine cardioprotection trial, and larger prospective studies that separate carvedilol’s cardiac benefits from any independent effects on tumor biology. If those data hold up, carvedilol could become a more confidently used part of supportive care for selected dogs receiving doxorubicin. (vet.tufts.edu)